Palvella Therapeutics Highlights Continued Progress Across Rare Skin Disease Pipeline with Two Poster Presentations at the 2026 American Academy of Dermatology Annual Meeting
Palvella Stock Up 340% as Insider Sells Shares. Here's What the Move Does (And Does Not) Signal [Yahoo! Finance]
Director Buys $500,000 Worth of Palvella Therapeutics Shares After Phase 3 Win [Yahoo! Finance]
Palvella Therapeutics (PVLA) had its price target raised by HC Wainwright from $255.00 to $270.00. They now have a "buy" rating on the stock.
Palvella Therapeutics to Host Full Year 2025 Financial Results Conference Call and Provide a Corporate Update on March 31, 2026 [TheStreet.com]